miRecule is a pre-clinical biotechnology company that develops RNA therapeutics using its DREAmiR genomics-based discovery platform, created through over a decade of NIH collaboration. The platform integrates genomic and clinical outcomes data to identify RNA targets and design chemically modified RNA therapeutics with targeted delivery. Its lead candidate, MC-30, is being advanced toward clinical development for head & neck cancer, and the company also has MC-DX4, an antisense oligonucleotide program for FSHD. miRecule intends to apply its platform across cancer, muscular dystrophy, and viral indications including HIV and COVID-19. The company spun out of the NIH into BioHealth Innovation’s incubator in 2017 and is based in Gaithersburg, Maryland. miRecule closed over $5.7M in seed funding, including a $2M non-dilutive Phase II SBIR grant from the National Cancer Institute.

Total raised

$6M

Funding rounds

2

Latest round

Seed

Latest activity

May 2021